-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Retension Pharmaceuticals with Outperform Rating, Announces Price Target of $50

Benzinga·11/03/2026 17:13:48
Listen to the news
Oppenheimer analyst Jay Olson initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Outperform rating and announces Price Target of $50.